Unlike therapies aimed at increasing BDNF or reducing the expression of mHTT, where earlier interventions will be more beneficial in delaying the progression of the disease, iPSC therapy has the potential to reduce HD symptoms at mid- and late-stages through the replacement of lost neurons. The gene discussed is BDNF; the disease is Huntington disease.